SB208 for the Treatment of Tinea Pedis
SB208 for the Treatment of Tinea Pedis
This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be
 conducted in non immunocompromised adult subjects with interdigital tinea pedis.
A phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be conducted
 in approximately 170 non immunocompromised adult subjects with interdigital tinea pedis.
 Subjects will apply the investigational product (IP) (SB208 or Vehicle Gel) to the
 interdigital areas and all affected and immediate surrounding areas of one or both feet once
 daily for 2 weeks, followed by a 4-week post-treatment observation period.
Inclusion Criteria:

 -  Otherwise healthy male and female subjects with clinical diagnosis of interdigital t.
 pedis

 -  T.pedis provisionally confirmed at baseline by a positive KOH wet mount for segmented
 fungal hyphae on skin scraping from the target site

 Exclusion Criteria:

 -  Women who are pregnant or nursing or planning on becoming pregnant

 -  Subjects with onychomycosis or moccasin-type t. pedis

 -  Subjects using topical or systemic anti-fungal agents